Literature DB >> 26237165

Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.

S Slot1, K Smits1, N W C J van de Donk1, B I Witte2, R Raymakers3, J J W M Janssen1, A E C Broers3, P A W Te Boekhorst4, S Zweegman1.   

Abstract

In myelofibrosis, the introduction of reduced-intensity conditioning (RIC) preceding allogeneic stem cell transplantation (SCT) resulted in lower transplant-related mortality rates compared with myeloablative conditioning. However, lowering the intensity of conditioning may increase the risk of graft failure in myelofibrosis, although hitherto this has not been indisputably proven. We here report the outcome of 53 patients who underwent allogeneic SCT with different conditioning regimens (RIC and non-myeloablative (NMA)) in three transplantation centers in the Netherlands. The cumulative incidence of graft failure within 60 days after SCT was high (28%), and this was primarily associated with the intensity of the conditioning regimen. Cumulative neutrophil engraftment at 60 days was lower in patients who received NMA conditioning compared with those who received RIC (56% vs 84%, P=0.03). Furthermore, of six patients who received a second transplantation after graft failure, the three patients with RIC regimens subsequently engrafted, whereas the three patients who received a second NMA regimen did not. This study indicates that in myelofibrosis, NMA regimens result in high engraftment failure rates. We propose the use of more intensive conditioning regimens, incorporating busulfan or melphalan.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26237165     DOI: 10.1038/bmt.2015.172

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  30 in total

1.  Restoration of the human stem cell niche after stem cell transplantation.

Authors:  Sonja Zweegman; Floortje L Kessler; Johanna W A M Celie; Jeroen J W M Janssen; Jacob van den Born; Gerrit J Schuurhuis; Angelika M Dräger
Journal:  Blood       Date:  2009-12-17       Impact factor: 22.113

2.  The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.

Authors:  W A Stewart; R Pearce; K E Kirkland; A Bloor; K Thomson; J Apperley; G McQuaker; D I Marks; C Craddock; S McCann; N Russell; G Cook; P D Kottaridis
Journal:  Bone Marrow Transplant       Date:  2010-02-15       Impact factor: 5.483

3.  Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

Authors:  Elisa Rumi; Daniela Pietra; Cristiana Pascutto; Paola Guglielmelli; Alejandra Martínez-Trillos; Ilaria Casetti; Dolors Colomer; Lisa Pieri; Marta Pratcorona; Giada Rotunno; Emanuela Sant'Antonio; Marta Bellini; Chiara Cavalloni; Carmela Mannarelli; Chiara Milanesi; Emanuela Boveri; Virginia Ferretti; Cesare Astori; Vittorio Rosti; Francisco Cervantes; Giovanni Barosi; Alessandro M Vannucchi; Mario Cazzola
Journal:  Blood       Date:  2014-07-01       Impact factor: 22.113

4.  Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study.

Authors:  P Guardiola; J E Anderson; G Bandini; F Cervantes; V Runde; W Arcese; A Bacigalupo; D Przepiorka; M R O'Donnell; P Polchi; A Buzyn; L Sutton; D Cazals-Hatem; G Sale; T de Witte; H J Deeg; E Gluckman
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

5.  Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Authors:  Marie Robin; Reza Tabrizi; Mohamad Mohty; Sabine Furst; Mauricette Michallet; Jacques-Olivier Bay; Jean-Yves Cahn; Eric De Coninck; Nathalie Dhedin; Marc Bernard; Bernard Rio; Agnès Buzyn; Anne Huynh; Karin Bilger; Pierre Bordigoni; Nathalie Contentin; Raphaël Porcher; Gérard Socié; Noel Milpied
Journal:  Br J Haematol       Date:  2010-12-07       Impact factor: 6.998

6.  The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries.

Authors:  J Abelsson; M Merup; G Birgegård; O WeisBjerrum; L Brinch; M Brune; P Johansson; M Kauppila; S Lenhoff; M Liljeholm; C Malm; K Remes; L Vindelöv; B Andréasson
Journal:  Bone Marrow Transplant       Date:  2011-05-09       Impact factor: 5.483

7.  Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.

Authors:  Daniella M B Kerbauy; Theodore A Gooley; George E Sale; Mary E D Flowers; Kristine C Doney; George E Georges; Joanne E Greene; Michael Linenberger; Effie Petersdorf; Brenda M Sandmaier; Bart L Scott; Mohamed Sorror; Derek L Stirewalt; F Marc Stewart; Robert P Witherspoon; Rainer Storb; Frederick R Appelbaum; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2007-03       Impact factor: 5.742

8.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

9.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Arturo Pereira; Paola Guglielmelli; Ester Pungolino; Marianna Caramella; Margherita Maffioli; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

10.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Authors:  Ayalew Tefferi; Juergen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Tiziano Barbui; Curtis A Hanson; Giovanni Barosi; Srdan Verstovsek; Gunnar Birgegard; Ruben Mesa; John T Reilly; Heinz Gisslinger; Alessandro M Vannucchi; Francisco Cervantes; Guido Finazzi; Ronald Hoffman; D Gary Gilliland; Clara D Bloomfield; James W Vardiman
Journal:  Blood       Date:  2007-05-08       Impact factor: 22.113

View more
  11 in total

1.  Increase of bone marrow macrophages and CD8+ T lymphocytes predict graft failure after allogeneic bone marrow or cord blood transplantation.

Authors:  N Kawashima; S Terakura; S Nishiwaki; D Koyama; Y Ozawa; M Ito; K Miyamura
Journal:  Bone Marrow Transplant       Date:  2017-04-03       Impact factor: 5.483

Review 2.  Allogeneic Stem Cell Transplantation in Myelofibrosis.

Authors:  Tania Jain; Ruben A Mesa; Jeanne M Palmer
Journal:  Biol Blood Marrow Transplant       Date:  2017-05-10       Impact factor: 5.742

Review 3.  Myelofibrosis: to transplant or not to transplant?

Authors:  Rebecca Devlin; Vikas Gupta
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

4.  Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.

Authors:  Juan Carlos Hernández-Boluda; Arturo Pereira; Nicolaus Kröger; Dietrich Beelen; Marie Robin; Martin Bornhäuser; Emanuele Angelucci; Antonin Vitek; Igor Wolfgang Blau; Riitta Niittyvuopio; Jürgen Finke; Jan J Cornelissen; Jakob Passweg; Peter Dreger; Eefke Petersen; Lothar Kanz; Jaime Sanz; Tsila Zuckerman; Nienke Zinger; Simona Iacobelli; Patrick Hayden; Tomasz Czerw; Donal McLornan; Ibrahim Yakoub-Agha
Journal:  Leukemia       Date:  2020-04-14       Impact factor: 11.528

Review 5.  The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation.

Authors:  Stefan O Ciurea; Kai Cao; Marcelo Fernandez-Vina; Piyanuch Kongtim; Monzr Al Malki; Ephraim Fuchs; Leo Luznik; Xiao-Jun Huang; Fabio Ciceri; Franco Locatelli; Franco Aversa; Luca Castagna; Andrea Bacigalupo; Massimo Martelli; Didier Blaise; Rupert Handgretinger; Denis-Claude Roy; Paul O'Donnell; Asad Bashey; Hillard M Lazarus; Karen Ballen; Bipin N Savani; Mohamad Mohty; Arnon Nagler
Journal:  Bone Marrow Transplant       Date:  2018-01-15       Impact factor: 5.483

6.  Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study.

Authors:  Vikas Gupta; Heidi E Kosiorek; Adam Mead; Rebecca B Klisovic; John P Galvin; Dmitriy Berenzon; Abdulraheem Yacoub; Auro Viswabandya; Ruben A Mesa; Judith Goldberg; Leah Price; Mohamed E Salama; Rona Singer Weinberg; Raajit Rampal; Noushin Farnoud; Amylou C Dueck; John O Mascarenhas; Ronald Hoffman
Journal:  Biol Blood Marrow Transplant       Date:  2018-09-08       Impact factor: 5.742

7.  Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis.

Authors:  Jan Philipp Bewersdorf; Amar H Sheth; Shaurey Vetsa; Alyssa Grimshaw; Smith Giri; Nikolai A Podoltsev; Lohith Gowda; Roni Tamari; Martin S Tallman; Raajit K Rampal; Amer M Zeidan; Maximilian Stahl
Journal:  Transplant Cell Ther       Date:  2021-05-28

Review 8.  A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.

Authors:  Erden Atilla; Pınar Ataca Atilla; Taner Demirer
Journal:  Balkan Med J       Date:  2017-01-05       Impact factor: 2.021

9.  [Risk-factors analysis of graft failure after allogeneic hematopoietic stem cell transplantation].

Authors:  Y Fei; X X Hu; Q Chen; A J Huang; H Cheng; X Ni; L Chen; L Gao; G S Tang; J Chen; W P Zhang; J M Yang; J M Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-01-14

Review 10.  Allogeneic hematopoietic stem-cell transplantation for myelofibrosis.

Authors:  Lining Zhang; Fan Yang; Sizhou Feng
Journal:  Ther Adv Hematol       Date:  2020-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.